NCT00195104View on ClinicalTrials.gov

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

September 17, 2003

Primary Completion Date

March 17, 2006

Study Completion Date

June 20, 2006

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

Arsenic Trioxide (Tricenox)

DRUG

Cytarabine

Trial Locations (1)

10021

Weill Medcial College of Cornell University, New York

All Listed Sponsors
lead

Weill Medical College of Cornell University

OTHER

NCT00195104 - Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML | Biotech Hunter | Biotech Hunter